Jaguar Health, Inc. — fact timeline

Jaguar Health, Inc. shareholders approved Ratification of the appointment of RBSM LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-07-07 meeting.

“2. Proposal to ratify the appointment of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 8,608,787 201,057 29,440 0”

Jaguar Health, Inc. shareholders approved Election of one Class II director to the Company's board of directors to hold office for a three-year term until the annual meeting of stockholders in 2026 and until his successor is elected and qualified. at the 2023-07-07 meeting.

“1. Proposal to elect one Class II director to the Company’s board of directors to hold officer for a three-year term until the annual meeting of stockholders in 2026 and until his successor is elected and qualified. The votes regarding this proposal were as follows: For Withheld Broker Non- Votes John Micek III 6,027,707 238,397 0”

Jaguar Health, Inc. entered into Streeterville Exchange Agreement with Streeterville Capital, LLC valued at Reduction of $1,726,888 in outstanding balance of August 2022 Royalty Interest in exchange for 73 sh (effective 2023-06-28).

“and (ii) a privately negotiated exchange agreement with Streeterville (the "Streeterville Exchange Agreement;" together with the Uptown Exchange Agreement, the "Exchange Agreement"), pursuant to which the Company issued an aggregate of 73 shares of Series H Convertible Preferred Stock to Streeterville, at an effective exchange price per share equal to the market price as of the date of the Streeterville Exchange Agreement, in exchange for a $1,726,888 reduction in the outstanding balance of the August 2022 Royalty Interest”

Jaguar Health, Inc. entered into Uptown Exchange Agreement with Uptown Capital, LLC valued at Reduction of $756,992 in outstanding balance of December 2020 Royalty Interest in exchange for 32 sh (effective 2023-06-28).

“On June 28, 2023, the Company entered into (i) a privately negotiated exchange agreement with Uptown (the "Uptown Exchange Agreement"), pursuant to which the Company issued an aggregate of 32 shares of the Company's newly authorized Series H Convertible Preferred Stock (the "Series H Preferred Stock") to Uptown, at an effective exchange price per share equal to the market price (defined as the Minimum Price under Nasdaq Listing Rule 5635(d)) as of the date of the Uptown Exchange Agreement, in exchange for a $756,992.00 reduction in the outstanding balance of the December 2020 Royalty Interest”

Jaguar Health, Inc. reported first quarter 2023 results: revenue $2.00 million.

“The combined net revenue for Mytesi ® and the Company’s other prescription product, Canalevia ® -CA1, which became commercially available in April 2022, was approximately $2.00 million in the first quarter of 2023”

Jaguar Health, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 10, 2023, Jaguar Health, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180 calendar day grace period, or until November 6, 2023, to regain compliance with the minimum bid price requirement. The continued listing standard”

Jaguar Health, Inc.: Created Series G Preferred Stock via Certificate of Designation, establishing its preferences, rights, and limitations.

“Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Series G Certificate of Designation As disclosed under Items 1.01 and 3.02 above, in connection with the Private Placement, the Company agreed to issue the Series G Preferred Stock to the Purchasers. The preferences, rights, limitations and other matters relating to the Series G Preferred Stock are set forth in the Certificate of Designation.”

Jaguar Health, Inc. reported the year ended December 31, 2022 results: revenue approximately $11.9 million.

“Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%.”

Jaguar Health, Inc. terminated License Agreement with SynWorld Technologies Corporation, C&E Telecom, LTD, and Tao Wang (effective 2023-01-31).

“On January 31, 2023, the Company, Licensee, C&E Telecom and Wang entered into a Mutual Termination of License Agreement (the “Termination Agreement”), pursuant to which the parties agreed to mutually terminate the License Agreement, effective as of January 31, 2023.”

Jaguar Health, Inc.: Filed Seventh Amendment to Certificate of Incorporation to effect a 1-for-75 reverse stock split of common stock (effective 2023-01-23).

“On January 20, 2023, the Company filed the Seventh Amendment with the Secretary of State of the State of Delaware, and the Reverse Stock Split will become effective in accordance with the terms of the Seventh Amendment at 12:01 am Eastern Time on January 23, 2023 (the "Effective Time").”

Jaguar Health, Inc. shareholders approved Approve one or more adjournments of the Special Meeting to solicit additional proxies if necessary at the 2023-01-20 meeting.

“Proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1 and 2, was approved by the stockholders by the following vote : For Against Abstained Broker Non- Votes 71,451,220 8,917,441 1,108,272 0”

Jaguar Health, Inc. shareholders approved Approve issuance of common stock equal to 20% or more of outstanding common stock in one or more non-public capital raising transactions at the 2023-01-20 meeting.

“Proposal to approve, pursuant to Nasdaq Marketplace Rule 5635(d), the issuance of Company’s common stock equal to 20% or more the Common Stock outstanding before the issuance in one or more non-public capital raising transaction, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 51,998,893 8,409,585 958,116 20,110,339”

Jaguar Health, Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-3 and not greater than 1-for-75 at the 2023-01-20 meeting.

“Proposal to approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share, at a ratio of not less than 1-for-3 and not greater than 1-for-75, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2024 without further approval or authorization of the Company’s stockholders, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 51,789,833,999 8,053,911,756 237,731,178 0”

Jaguar Health, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(3)(A)(iii)).

“January 5, 2023, Jaguar Health, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the bid price for the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”), had closed below $0.10 per share for the preceding ten consecutive trading days, in contravention of Nasdaq Listing Rule 5810(3)(A)(iii) (the “$0.10 Rule”), the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) to appea”

Jaguar Health, Inc.: Filed Certificate of Designation for Series F Preferred Stock, establishing the preferences, rights, and limitations of the new series (effective 2022-11-10).

“The terms of the Series F Preferred Stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series F Preferred Stock (the “Certificate of Designation”) filed with the Secretary of State of Delaware (the “DE SOS”) and effective on November 10, 2022.”

Jaguar Health, Inc. entered into Securities Purchase Agreement with SynWorld Technologies Corporation valued at $100 (effective 2022-11-11).

“On November 11, 2022, Jaguar Health, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with SynWorld Technologies Corporation (“SynWorld”), pursuant to which the Company agreed to issue, in a private placement (the “Preferred Issuance Transaction”), an aggregate of ten shares (the “Series F Preferred Shares”) of the Company’s Series F Preferred Stock, par value $0.0001 per share (“Series F Preferred Stock”), at a price per share equal to the Series F Original Issue Price (as defined below) for gross proceeds of $100.”

Jaguar Health, Inc. reported third quarter 2022 results: revenue approximately $3.1 million.

“The combined net revenue for Mytesi ® and the Company’s other prescription product, Canalevia ® -CA1, which became commercially available in April 2022, was approximately $3.1 million in the third quarter of 2022, representing an increase of 8.2% over prescription product net revenue in the second quarter of 2022, which totaled approximately $2.9 million, and an increase of approximately 412% over Mytesi net revenue in the third quarter of 2021, which totaled approximately $0.6 million.”

Anula Jayasuriya was appointed as Class III Director at Jaguar Health, Inc..

“the Board, by resolution as contemplated in the Company’s bylaws, appointed Dr. Anula Jayasuriya to fill the vacancy created by Mr. Divis’s resignation and serve as Class III director of the Company”

Greg J. Divis resigned as Member of the Board at Jaguar Health, Inc..

“Mr. Greg J. Divis notified the Board of Directors (the “Board”) of Jaguar Health, Inc. (the “Company”) of his intention to resign as a member of the Board, effective as of July 1, 2022.”